Brokerages Anticipate AzurRx BioPharma (AZRX) to Post ($0.18) EPS

AzurRx BioPharma (NASDAQ:AZRX) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Brokerages have set a one year consensus target price of $9.17 for the company and are anticipating that the company will post ($0.18) EPS for the current quarter, according to Zacks. Zacks has also assigned AzurRx BioPharma an industry rank of 146 out of 265 based on the ratings given to its competitors.

Several equities research analysts have recently weighed in on the company. HC Wainwright set a $8.00 price objective on AzurRx BioPharma and gave the stock a “buy” rating in a research note on Tuesday, April 24th. ValuEngine raised AzurRx BioPharma from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

Shares of NASDAQ AZRX opened at $2.60 on Friday. AzurRx BioPharma has a 1 year low of $2.31 and a 1 year high of $5.25.

An institutional investor recently raised its position in AzurRx BioPharma stock. Ardsley Advisory Partners lifted its stake in shares of AzurRx BioPharma (NASDAQ:AZRX) by 32.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,500 shares of the company’s stock after acquiring an additional 20,000 shares during the quarter. Ardsley Advisory Partners owned 0.71% of AzurRx BioPharma worth $300,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 4.99% of the company’s stock.

AzurRx BioPharma Company Profile

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

Get a free copy of the Zacks research report on AzurRx BioPharma (AZRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with's FREE daily email newsletter.

Leave a Reply